KRAS and pancreatic neoplasm: Compared with the ubiquitin‐dependent degradation of the KRAS oncoprotein, the targeted “knockdown” of KRAS at the post‐translational level through the ODC/AZ pathway (we also call it “proteasome‐dependent”) is similarly effective, which may represent an additional valid therapeutic strategy in pancreatic cancers.